Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06810544 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
191
Enrollment target
13
Study locations

NCT06810544 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 191 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06810544, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Tango Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
191 participants
Enrollment target
13
Study locations

Study Summary

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Conditions Studied

Non-Small Cell Lung Cancer Lung Cancer Solid Tumor Brain Tumor Glioma, Malignant Glioma Glioblastoma Multiforme Non-Small Cell Adenocarcinoma

Interventions

  • DRUG TNG456
  • DRUG abemaciclib

Study Locations (13)

New York

  • NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Arizona

  • Mayo Clinic Scottsdale - Scottsdale

California

  • University of California, Irvine - Irvine

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Illinois

  • Northwestern Memorial Hospital - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester

Trial Details

FieldValue
Enrollment Target 191 participants
Start Date 2025-03-24
Est. Completion 2027-09-30
Phase Phase 1

Sponsor

Tango Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06810544

The ClinicalTrials.gov registry entry for NCT06810544 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which TNG456 is the first listed.

NCT06810544 reports 13 study locations spanning 12 distinct geographic areas - top geographies include New York, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06810544 about?

NCT06810544 is a clinical study titled "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss". This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumo...

What is the current status of trial NCT06810544?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2025-03-24. Estimated completion is 2027-09-30.

What conditions does trial NCT06810544 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Solid Tumor, Brain Tumor, Glioma, Malignant.

What interventions are being tested in trial NCT06810544?

The interventions under investigation include: TNG456 (DRUG), abemaciclib (DRUG).

Who is sponsoring clinical trial NCT06810544?

This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06810544 being conducted?

This trial has 13 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.